Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we discuss why a cell therapy stalwart is pivoting, and why a Feng Zhang startup is laying off a quarter of its staff. Also, Novartis is using some of its GLP-1 windfall to invest in Flagship Pioneering startups in the cardiometabolic space.
The need-to-know this morning
We’ve got a news lull ahead of next week’s all-encompassing J.P. Morgan Healthcare Conference in San Francisco. Inhale. Relax. Exhale.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect